These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 28355078)

  • 1. Discovery of Novel Indazole Derivatives as Orally Available β
    Wada Y; Nakano S; Morimoto A; Kasahara KI; Hayashi T; Takada Y; Suzuki H; Niwa-Sakai M; Ohashi S; Mori M; Hirokawa T; Shuto S
    J Med Chem; 2017 Apr; 60(8):3252-3265. PubMed ID: 28355078
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of Novel Indazole Derivatives as Highly Potent and Selective Human β3-Adrenergic Receptor Agonists with the Possibility of Having No Cardiovascular Side Effects.
    Wada Y; Shirahashi H; Iwanami T; Ogawa M; Nakano S; Morimoto A; Kasahara K; Tanaka E; Takada Y; Ohashi S; Mori M; Shuto S
    J Med Chem; 2015 Aug; 58(15):6048-57. PubMed ID: 26125514
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of benzamides as potent human β3 adrenergic receptor agonists.
    Zhu C; Kar NF; Li B; Costa M; Dingley KH; Di Salvo J; Ha SN; Hurley AL; Li X; Miller RR; Salituro GM; Struthers M; Weber AE; Hale JJ; Edmondson SD
    Bioorg Med Chem Lett; 2016 Jan; 26(1):55-9. PubMed ID: 26590100
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of a novel and potent human and rat beta3-adrenergic receptor agonist, [3-[(2R)-[[(2R)-(3-chlorophenyl)-2-hydroxyethyl]amino]propyl]-1H-indol-7-yloxy]acetic acid.
    Harada H; Hirokawa Y; Suzuki K; Hiyama Y; Oue M; Kawashima H; Kato H; Yoshida N; Furutani Y; Kato S
    Chem Pharm Bull (Tokyo); 2005 Feb; 53(2):184-98. PubMed ID: 15684518
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent developments in the design of orally bioavailable beta3-adrenergic receptor agonists.
    Sawa M; Harada H
    Curr Med Chem; 2006; 13(1):25-37. PubMed ID: 16457637
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of an orally bioavailable alkyl oxadiazole beta3 adrenergic receptor agonist.
    Feng DD; Biftu T; Candelore MR; Cascieri MA; Colwell LF; Deng L; Feeney WP; Forrest MJ; Hom GJ; MacIntyre DE; Miller RR; Stearns RA; Strader CD; Tota L; Wyvratt MJ; Fisher MH; Weber AE
    Bioorg Med Chem Lett; 2000 Jul; 10(13):1427-9. PubMed ID: 10888324
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TRK-380, a novel selective human β3-adrenoceptor agonist, ameliorates formalin-induced pollakiuria in rats and carbachol-induced bladder contraction in dogs.
    Kanie S; Otsuka A; Yoshikawa S; Kobayashi R; Itaba S; Yokokawa H; Tajima Y; Ozono S; Hayashi R; Mochizuki H
    Urology; 2013 Oct; 82(4):975.e7-975.e12. PubMed ID: 24075004
    [TBL] [Abstract][Full Text] [Related]  

  • 8. GW427353 (solabegron), a novel, selective beta3-adrenergic receptor agonist, evokes bladder relaxation and increases micturition reflex threshold in the dog.
    Hicks A; McCafferty GP; Riedel E; Aiyar N; Pullen M; Evans C; Luce TD; Coatney RW; Rivera GC; Westfall TD; Hieble JP
    J Pharmacol Exp Ther; 2007 Oct; 323(1):202-9. PubMed ID: 17626794
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early investigational β3 adreno-receptor agonists for the management of the overactive bladder syndrome.
    Thiagamoorthy G; Giarenis I; Cardozo L
    Expert Opin Investig Drugs; 2015; 24(10):1299-306. PubMed ID: 26292923
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, synthesis, and evaluation of conformationally restricted acetanilides as potent and selective β3 adrenergic receptor agonists for the treatment of overactive bladder.
    Moyes CR; Berger R; Goble SD; Harper B; Shen DM; Wang L; Bansal A; Brown PN; Chen AS; Dingley KH; Di Salvo J; Fitzmaurice A; Gichuru LN; Hurley AL; Jochnowitz N; Miller RR; Mistry S; Nagabukuro H; Salituro GM; Sanfiz A; Stevenson AS; Villa K; Zamlynny B; Struthers M; Weber AE; Edmondson SD
    J Med Chem; 2014 Feb; 57(4):1437-53. PubMed ID: 24437735
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Investigation of piperazine benzamides as human β
    Harper BH; Wang L; Zhu C; Kar NF; Li B; Moyes CR; Goble SD; Costa M; Dingley K; Di Salvo J; Ha SN; Hurley A; Li X; Miller RR; Nagabukuro H; Salituro GM; Smith S; Struthers M; Hale JJ; Edmondson SD; Berger R
    Bioorg Med Chem Lett; 2017 Feb; 27(4):1094-1098. PubMed ID: 28089699
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and SAR of benzyl and phenoxymethylene oxadiazole benzenesulfonamides as selective beta3 adrenergic receptor agonist antiobesity agents.
    Biftu T; Feng DD; Liang GB; Kuo H; Qian X; Naylor EM; Colandrea VJ; Candelore MR; Cascieri MA; Colwell LF; Forrest MJ; Hom GJ; MacIntyre DE; Stearns RA; Strader CD; Wyvratt MJ; Fisher MH; Weber AE
    Bioorg Med Chem Lett; 2000 Jul; 10(13):1431-4. PubMed ID: 10888325
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression and possible functional role of the beta3-adrenoceptor in human and rat detrusor muscle.
    Fujimura T; Tamura K; Tsutsumi T; Yamamoto T; Nakamura K; Koibuchi Y; Kobayashi M; Yamaguchi O
    J Urol; 1999 Feb; 161(2):680-5. PubMed ID: 9915482
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Species differences in the distribution of beta-adrenoceptor subtypes in bladder smooth muscle.
    Yamazaki Y; Takeda H; Akahane M; Igawa Y; Nishizawa O; Ajisawa Y
    Br J Pharmacol; 1998 Jun; 124(3):593-9. PubMed ID: 9647486
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The selectivity of beta-adrenoceptor antagonists at the human beta1, beta2 and beta3 adrenoceptors.
    Baker JG
    Br J Pharmacol; 2005 Feb; 144(3):317-22. PubMed ID: 15655528
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of Vibegron: A Potent and Selective β3 Adrenergic Receptor Agonist for the Treatment of Overactive Bladder.
    Edmondson SD; Zhu C; Kar NF; Di Salvo J; Nagabukuro H; Sacre-Salem B; Dingley K; Berger R; Goble SD; Morriello G; Harper B; Moyes CR; Shen DM; Wang L; Ball R; Fitzmaurice A; Frenkl T; Gichuru LN; Ha S; Hurley AL; Jochnowitz N; Levorse D; Mistry S; Miller RR; Ormes J; Salituro GM; Sanfiz A; Stevenson AS; Villa K; Zamlynny B; Green S; Struthers M; Weber AE
    J Med Chem; 2016 Jan; 59(2):609-23. PubMed ID: 26709102
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Substituted oxazole benzenesulfonamides as potent human beta3 adrenergic receptor agonists.
    Ok HO; Reigle LB; Candelore MR; Cascieri MA; Colwell LF; Deng L; Feeney WP; Forrest MJ; Hom GJ; MacIntyre DE; Strader CD; Tota L; Wang P; Wyvratt MJ; Fisher MH; Weber AE
    Bioorg Med Chem Lett; 2000 Jul; 10(14):1531-4. PubMed ID: 10915043
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selective β₃-adrenoceptor agonists for the treatment of overactive bladder.
    Andersson KE; Martin N; Nitti V
    J Urol; 2013 Oct; 190(4):1173-80. PubMed ID: 23458471
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of (R)-2-(2-aminothiazol-4-yl)-4'-{2-[(2-hydroxy-2-phenylethyl)amino]ethyl} acetanilide (YM178), a novel selective beta3-adrenoceptor agonist, on bladder function.
    Takasu T; Ukai M; Sato S; Matsui T; Nagase I; Maruyama T; Sasamata M; Miyata K; Uchida H; Yamaguchi O
    J Pharmacol Exp Ther; 2007 May; 321(2):642-7. PubMed ID: 17293563
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined treatment with a β
    Imamura T; Ogawa T; Minagawa T; Nagai T; Suzuki T; Saito T; Yokoyama H; Nakazawa M; Ishizuka O
    Neurourol Urodyn; 2017 Apr; 36(4):1026-1033. PubMed ID: 27367573
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.